| Dec, 17 | Roche to take part in Expo.02 more.. |
| Dec, 6 | Roche to spin off fragrances and flavours division - Sharp focus on healthcare business more.. |
| Dec, 6 | New member to join Roche Executive Committee more.. |
| Nov, 3 | Class action suits with US bulk vitamin customers settled more.. |
| Oct, 28 | Roche receives FDA approval for Tamiflu more.. |
| Oct, 21 | Roche prices the successful offering of Genentech shares more.. |
| Oct, 20 | Roche determines not to proceed with the offering of the exchangeable bond more.. |
| Oct, 18 | Roche starts vitamin A production in China more.. |
| Oct, 14 | Roche continues to post strong growth in third quarter more.. |
| Oct, 8 | Roche intends to offer additional shares of Genentech and to issue exchangeable bond more.. |
| Nov, 24 | First Approval of Roche's Tamiflu®, a breakthrough flu treatment in a pill more.. |
| Nov, 9 | Roche to license Bioinformatics Software from deCODE genetics more.. |
| Nov, 7 | Roche and Zeiss set new global standard for screening systems more.. |
| Aug, 19 | Significant improvement in results for the first Half of 1999 more.. |
| Aug, 6 | Roche announces results of phase III study of the first oral glycoprotein IIB/IIIA receptor antagonist for treatment of acute coronary syndromes more.. |
| Aug, 2 | Roche receives marketing clearance in first European country for Herceptin® more.. |
| Jul, 20 | Roche publicly offers 20 million shares of Genentech Common Stock at a price of $97 more.. |
| Jul, 13 | Marked sales growth at Roche more.. |
| Jul, 12 | Roche and Trimeris sign Agreement to Develop Trimeris's compounds more.. |
| Jul, 1 | Roche invests heavily to expand site in Upper Bavaria more.. |
| Jun, 21 | International Roche R&D Media Conference 1999 - Basel, 14/15 June 1999 more.. |
| Jun, 21 | EU approval for Roferon-A® (interferon alfa-2a) for the adjuvant treatment of malignant melanoma more.. |
| Jun, 14 | Roche exercises option to redeem Genentech shares more.. |
| Jun, 3 | Roche intends to exercise its Genentech call option more.. |
| May, 26 | Shareholders with pooled voting rights retain majority holding more.. |
| May, 21 | Media Conference more.. |
| May, 20 | Agreement between Roche and US Department of Justice more.. |
| May, 20 | Roche announces Management Changes more.. |
| Apr, 29 | Roche to transfer OTC headquarters from Geneva to Basel more.. |
| Apr, 26 | FDA approves Xenical (orlistat) more.. |
| Apr, 20 | Roche holds 1999 Annual General Meeting more.. |
| Apr, 15 | Sustained dynamic growth more.. |
| Mar, 26 | Roche and deCode Genetics Announce Progress in Osteoarthritis Research Program more.. |
| Mar, 9 | Profits up again at Roche more.. |
| Mar, 4 | Zenapax® (daclizumab), the first humanized monoclonal antibody to prevent organ rejection, approved in the European Union more.. |
| Mar, 3 | Roche receives FDA approval for most sensitive HIV test more.. |
| Feb, 10 | Invirase® awarded prestigious International Prix Galien more.. |
| Feb, 1 | Roche recovers marketing rights for cardiovascular medicine carvedilol more.. |
| Jan, 20 | Xenical®: Significant weight loss benefits proven in biggest study ever more.. |
| Jan, 14 | Roche Group continues strong sales growth through 1998 more.. |
| Jan, 11 | New global OTC head at Roche more.. |
print this page